eXoZymes Reports Third Quarter 2026 Financial Results and Business Update
11/20/2026
Impact: 60
Healthcare
eXoZymes reported a third-quarter 2026 net loss of $2.24 million and operating expenses of $3.05 million. Its $3.26 million cash balance is expected to fund operations through early 2027. The company rebranded its lead nutraceutical ingredient as Tyferyn and began technology transfer with commercial-scale manufacturing partner Curia in the fourth quarter. Two pipeline candidates, SAPPHIRE for joint comfort and AMETHYST for mental stress and energy, reached proof of concept as eXoZymes advances its cell-free biomanufacturing platform toward commercial readiness.
AI summary, not financial advice
Share: